AstraZeneca’s Alexion division has received FDA approval for Koselugo (selumetinib) to treat adults with NF1 who have symptomatic, inoperable plexiform neurofibromas. The decision is based on strong ...
The global wine enzymes market is poised for robust growth, with an estimated valuation of USD 1.5 billion in 2025. The ...
The outlook for the KLKB1 inhibitors market is increasingly positive, driven by growing recognition of the kallikrein–kinin ...
Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback